NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

Inclusion Criteria:

• Aged ≥ 18 years

• Decision to start first-line (1L) treatment with TDC according to the current SmPCs

• Histologically or cytologically confirmed diagnosis of NSQ mNSCLC (incl. LCNEC ifconsidered NSCLC-like by the treating physician)

• No sensitizing epidermal growth factor receptor (EGFR) mutations or anaplasticlymphoma kinase (ALK) alterations

• Molecular Next Generation Sequencing (NGS) panel as per institutional standard hasbeen initiated (including the following genes: KRAS, STK11, KEAP1, and TP53)

• TTF-1 expression analysis has been initiated

• PD-L1 expression analysis has been initiated

• Women of childbearing potential must use effective contraception during treatmentwith durvalumab and for at least 3 months after the last dose of durvalumab

• Ability to understand the study concept

• Provision of signed informed consent form in accordance with applicable localprovisions

Exclusion Criteria:

• Current participation in interventional clinical trials

• Contraindications according to current SmPCs

• Any active tumor other than metastatic NSCLC